- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Phase 3 Trial Results Found New Meloxicam/Rizatriptan Drug Reduces Migraine Pain
Results of the phase 3 INTERCEPT trial showed that patients who received treatment with novel AXS-07 had substantially reduced migraine pain.
Results of the phase 3 INTERCEPT trial showed that treatment with the investigational therapy AXS-07 substantially reduced migraine pain and significantly prevented the progression of migraine pain intensity.
AXS-07 is an oral, multi-mechanistic agent that consists of the nonsteroidal anti-inflammatory drug meloxicam and rizatriptan, a 5-HT1B/1D agonist. It is being developed by Axsome Therapeutics and is thought to decrease neuroinflammation, pain signal transmission, and central sensitization through calcitonin gene-related peptide inhibition.
“With INTERCEPT and the previously completed MOMENTUM Phase 3 trial in patients with a history of inadequate response to prior acute treatments, AXS-07 has now been evaluated in two positive well-controlled trials,” said Herriot Tabuteau, MD, chief executive officer of Axsome Therapeutics, in a company press release. “These trials demonstrate the efficacy of AXS-07 against potent active and placebo comparators, across a spectrum of migraine attack settings, regardless of the timing of migraine treatment, disease severity, or baseline pain intensity.”
The randomized, double-blind, placebo-controlled study included 302 patients who received either a single dose of AXS-07 or placebo at the first sign of migraine pain, when the pain intensity was considered mild.
The co-primary endpoints in the study were the proportion of patients free from headache pain 2 hours after dosing and the proportion of patients who did not experience their most troublesome migraine-associated symptoms 2 hours after dosing.
The results showed that, compared to placebo, a statistically significantly greater percentage of patients treated with AXS-07 achieved pain freedom (32.6% vs 16.3%, P=.002) and freedom from the most bothersome symptom (43.9% vs 26.7%, P=.003) 2 hours after dosing.
Statistical significance for freedom from migraine pain was achieved at 90 minutes with AXS-07 (P=.003) and at every time thereafter.
The results also suggest that patients treated with AXS-07 were more likely to experience sustained pain freedom vs patients who received placebo from 2-24 hours after dosing (22.7% vs 12.6%, respectively; P=.03) and from 2-48 hours after dosing (20.5% vs 9.6%, respectively; P=0.13)
Other key findings include:
·73.5% of AXS-07 patients did not experience progression of migraine pain beyond mild intensity 2-24 hours after dosing vs 47.4% of placebo patients (P<.001)
·Fewer AXS-07 patients utilized rescue medication over 24 hours vs placebo patients (15.3% vs 42.2%, respectively; P<.001)
·73.5% of AXS-07 patients achieved the ability to perform normal activities at 24 hours vs 47.7% of placebo patients (P<.001).
Axsome Therapeutics plans to submit a new drug application for AXS-07 to the US Food and Drug Administration in the fourth quarter of 2020.
For more COVID-19 coverage for primary care, visit our COVID-19 Resource Page.
